RxDoctor Payments Data

Lowell McCauley, MD

Obstetrics & Gynecology · Knoxville, TNNPI 1003850280

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $14,625 of the $21,286 with a category attached, or 68.7%. Astellas Pharma US Inc accounts for 65.9% of it on its own, with 21 other manufacturers making up the rest. Reporting peaked in 2023 at $13,004 and has fallen 93.4% since, to $856 in 2025. Among obstetrics & gynecology clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$21,286in general payments, 2019–2025

Across 52 payments — averaging $409.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$14K
  • Asensus Surgical, Inc.$4K
  • Duchesnay USA Incorporated$2K
  • Merz North America, Inc.$189
  • Convatec Inc.$159
  • Medtronic$145
  • plus $626 from 16 others

What the payments were for

  • Consulting fees$3,75018%
  • Speaking & faculty fees$14,62569%
  • Travel & lodging$1,5257%
  • Food & beverage$1,2956%
  • Education$910%

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,286 in reported general payments places this provider in the 95th percentile of 763 obstetrics & gynecology providers in Tennessee.

See all obstetrics & gynecology providers in Tennessee

Medicare billing

Part B allowed, 2024
$75,460
Medicare patients
65
Services billed
528

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron11$9,794
Estradiol44$1,379
Risedronate Sodium13$723
ProgesteroneProgesterone, Micronized15$648
Oxybutynin Chloride ErOxybutynin Chloride13$486
Medroxyprogesterone Acetate36$392
Alprazolam28$195
Levothyroxine Sodium20$193
Spironolactone17$161
Escitalopram Oxalate11$159
Alendronate Sodium13$88
Atorvastatin Calcium14$67
Clonazepam13$36

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$14,018$9,79411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 763 obstetrics & gynecology providers in Tennessee.

Other obstetrics & gynecology in Knoxville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →